Gabapentin Solution
Product Images NDC 42192-608

10 FDA label images from Acella Pharmaceuticals, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 42192-608). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Acella Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

The Equation Of Cockcroft And Gault (Figure 01)

The Equation Of Cockcroft And Gault (Figure 01)
An illustration showing the formula for calculating creatinine clearance (CLCr). The formula incorporates patient age in years, weight in kilograms, serum creatinine in mg/dL, and includes an adjustment factor of 0.85 for female patients.*
FDA Label Image

Structural Formula Of Gabapentin (Figure 02)

Structural Formula Of Gabapentin (Figure 02)
Chemical structure of gabapentin showing a cyclohexane ring attached to an aminomethyl group and an acetic acid side chain.*
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Figure 03)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Figure 03)
A line graph depicting mean pain scores over time in weeks during a clinical trial comparing placebo and Gabapentin 3600 mg/day. The horizontal axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The vertical axis shows mean pain scores from 0 to 10, with Gabapentin showing a decreasing trend compared to placebo throughout the 8 weeks.*
FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Figure 04)

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Figure 04)
A line graph showing mean pain score over 7 weeks with a 3-week dose titration period followed by a 4-week fixed dose period. It compares placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day, with pain scores decreasing over time in gabapentin groups more than placebo.*
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Figure 05)

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Figure 05)
A bar chart comparing results from two studies labeled Study 1 and Study 2. The chart shows percentages on the vertical axis from 0% to 100%, with bars representing different groups: placebo (PBO) and gabapentin (GBP) at specified doses (3600 mg in Study 1; 1800 mg and 2400 mg in Study 2). Statistical significance is indicated by asterisks (** p < 0.01, *** p < 0.001) above relevant bars.*
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Figure 06)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Figure 06)
A chart showing percentage difference versus daily dose in milligrams (mg) for Gabapentin. It compares three studies labeled a, b, and c, with percentage differences plotted for daily doses of 600, 900, 1200, and 1800 mg. Study a uses black squares, study b uses gray squares, and study c uses white squares.*
FDA Label Image

Logo (Figure 07)

Logo (Figure 07)
FDA Label Image

Principal Display Panel (5 mL unit dose cups, boxes of 40)

Principal Display Panel (5 mL unit dose cups, boxes of 40)
Gabapentin 250 mg/5 mL oral solution label from Acella Pharmaceuticals, LLC. The label states each 5 mL contains 250 mg of gabapentin, and it should be kept refrigerated. It is marked for institutional use only and includes lot number, expiration date, manufacturer contact information, and a barcode.*
FDA Label Image

Principal Display Panel (6 mL unit dose cups, boxes of 40)

Principal Display Panel (6 mL unit dose cups, boxes of 40)
Gabapentin oral solution label showing 300 mg/6 mL strength in a 6 mL delivery volume. The label states the product is for institutional use only and should be kept refrigerated. It includes manufacturer information: Acella Pharmaceuticals, LLC, Alpharetta, GA, and has an expiration date of May 11, 2020.*
FDA Label Image

Principal Display Panel (470 mL Bottle Label)

Principal Display Panel (470 mL Bottle Label)
Gabapentin Oral Solution 250 mg/5 mL label for oral use, containing 470 mL per bottle. This prescription drug label from Acella Pharmaceuticals, LLC includes dosage strength, usage warnings, storage instructions, and a note to dispense medication guide with each prescription. The label also states the product contains xylitol and is not for veterinary use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.